New York, NY (February 6, 2025) – Canopy today announced that it has been named to the 2025 New York Digital Health 100 (DH100), a recognition that highlights the most exciting and innovative startups in New York. Digital Health New York (DHNY) publishes the annual list in conjunction with the 2025 New York Healthcare Innovation Report which analyzes the digital health sector's investment trends, challenges, and opportunities.
Canopy Named to the New York Digital Health 100
for Second Consecutive Year
DH100 recognizes standout companies that have helped make New York the capital of healthcare innovation
Canopy, the first Continuous Care Platform for oncology, supports care teams by monitoring patients between office visits, streamlining care to drive rapid resolution, and capturing meaningful revenue through programs like Remote Therapeutic Monitoring, Principal Care Management, and Principal Illness Navigation.
“Canopy saw record growth over the last year, and we are now contracted to serve more than 2,000 oncology providers—approximately 10% of the US market. We’re proud to be at the forefront of AI-powered, continuous oncology care and to be recognized among the New York Digital Health 100 for the second consecutive year."
—Lavi Kwiatkowsky, Founder and CEO, Canopy.
In 2024, Canopy announced new partnerships with leading cancer centers nationwide, including The Toledo Clinic Cancer Centers, Oncology Consultants, and Cancer Care Specialists of Illinois. Canopy also announced a partnership with Flatiron Health to streamline continuous care management for practices using Flatiron’s OncoEMR®.
Presentations highlighting the potential impact of Canopy’s platform on oncology patient experience in real-world settings have demonstrated:
45% improvement in treatment persistence at three months¹
22% reduction in ER visits/hospitalizations per 100 patient months²
88% patient engagement sustained at six months³
Most recently, at the 2024 American Society of Hematology (ASH) meeting, Canopy presented new data highlighting:
37% reduction in treatment discontinuation at three months⁴
Improved early detection of toxicities with bispecific antibody therapies⁵
“Now in its sixth year, the New York DH100 has evolved and grown, and in that time, the digital health ecosystem in New York has also reached unprecedented levels of innovation and impact. We are honored to celebrate these organizations, whose dedication to transformation and progress is driving the future of healthcare.”
—Bunny Ellerin, Co-Founder and CEO, DHNY
To download a copy of the New York Healthcare Innovation Report, please click here.
About Canopy
Canopy provides oncology practices with a comprehensive platform for all the care that happens between visits. Canopy’s Continuous Care Platform enables practices to identify and prioritize patients who need help, resolve their issues using intelligent software, and generate new reimbursement streams from high-quality care. Over the past year, Canopy has grown its provider base by 4X, now contracted to serve more than 2,000 providers across prominent practices nationwide. For more information, visit www.canopycare.us.
About Digital Health New York (DHNY)
Digital Health New York (DHNY) is a connected community of digital health leaders who share ideas, spark new directions and create success across the entire ecosystem. As an organization, we seek to increase the visibility of New York City as a leader in healthcare innovation and showcase the companies and leaders creating the future of healthcare. Our flagship event, DHNY Summit, brings together an elite group of entrepreneurs, investors, payers, providers and executives to cultivate the New York digital health community and drive impactful conversations around the current and future state of digital health. DHNY was founded in 2022 in collaboration with AlleyCorp. For more information or to join DHNY’s mailing list, please visit www.dhny.co.
DH100 Methodology
To compile the DH100, we invited companies to complete an in-depth application with both quantitative and qualitative measures to help us to get to know the company better. We also used our dynamic database of digital health companies in the region to round out the consideration set. A company qualified for consideration if it maintained headquarters or employed at least 5 people in the New York region. Companies that were public or non-profit; founded before 2014; or had an exit were excluded. We evaluated companies on a number of factors, including but not limited to: strength of application, leadership, number of employees, funding , revenue , market fit, differentiated offerings, and community engagement.
Media Contact
1 Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. Journal of Clinical Oncology, 40(16_suppl), 1528. DOI: 10.1200/JCO.2022.40.16_suppl.1528
2 Kolodziej, M. A., Kwiatkowsky, L., Parrinello, C., Thurow, T., Schaefer, E. S., Beck, J. T., Cherny, N., & Blau, S. (2022). ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. Journal of Clinical Oncology, 40(16_suppl), 1508
3 Cherny, N. I., Parrinello, C. M., Kwiatkowsky, L., Hunnicutt, J., Beck, T., Schaefer, E., Thurow, T., & Kolodziej, M. (2022). Feasibility of Large-Scale Implementation of an Electronic Patient- Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center. JCO Oncology Practice, 18(12), e1918-e1926. DOI: 10.1200/OP.22.00180
4 Essell, J. H., Derman, B. A., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 8). Symptoms detection among patients with lymphoid malignancies (LM) using electronic patient-reported outcomes (ePROs) in community hematology-oncology clinics. American Society of Hematology Annual Meeting
5 Derman, B. A., Essell, J. H., Kolodziej, M. A., Kwiatkowsky, L., Calkins, G., Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting